Role of positron emission tomography/computed tomography in breast cancer

Austin Bourgeois, Lance A. Warren, Ted T. Chang, Scott Embry, Kathleen Hudson, Yong Bradley

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Although positron emission tomography (PET) imaging may not be used in the diagnosis of breast cancer, the use of PET/computed tomography is imperative in all aspects of breast cancer staging, treatment, and follow-up. PET will continue to be relevant in personalized medicine because accurate tumor status will be even more critical during and after the transition from a generic metabolic agent to receptor imaging. Positron emission mammography is an imaging proposition that may have benefits in lower doses, but its use is limited without new radiopharmaceuticals.

Original languageEnglish (US)
Pages (from-to)781-798
Number of pages18
JournalRadiologic Clinics of North America
Volume51
Issue number5
DOIs
StatePublished - Jan 1 2013

Fingerprint

Positron-Emission Tomography
Breast Neoplasms
Precision Medicine
Radiopharmaceuticals
Neoplasm Staging
Mammography
Electrons
Neoplasms
Positron Emission Tomography Computed Tomography
Therapeutics

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Role of positron emission tomography/computed tomography in breast cancer. / Bourgeois, Austin; Warren, Lance A.; Chang, Ted T.; Embry, Scott; Hudson, Kathleen; Bradley, Yong.

In: Radiologic Clinics of North America, Vol. 51, No. 5, 01.01.2013, p. 781-798.

Research output: Contribution to journalReview article

Bourgeois, Austin ; Warren, Lance A. ; Chang, Ted T. ; Embry, Scott ; Hudson, Kathleen ; Bradley, Yong. / Role of positron emission tomography/computed tomography in breast cancer. In: Radiologic Clinics of North America. 2013 ; Vol. 51, No. 5. pp. 781-798.
@article{1144d19bb48b4b3eb265d11a1de13581,
title = "Role of positron emission tomography/computed tomography in breast cancer",
abstract = "Although positron emission tomography (PET) imaging may not be used in the diagnosis of breast cancer, the use of PET/computed tomography is imperative in all aspects of breast cancer staging, treatment, and follow-up. PET will continue to be relevant in personalized medicine because accurate tumor status will be even more critical during and after the transition from a generic metabolic agent to receptor imaging. Positron emission mammography is an imaging proposition that may have benefits in lower doses, but its use is limited without new radiopharmaceuticals.",
author = "Austin Bourgeois and Warren, {Lance A.} and Chang, {Ted T.} and Scott Embry and Kathleen Hudson and Yong Bradley",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.rcl.2013.06.003",
language = "English (US)",
volume = "51",
pages = "781--798",
journal = "Radiologic Clinics of North America",
issn = "0033-8389",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Role of positron emission tomography/computed tomography in breast cancer

AU - Bourgeois, Austin

AU - Warren, Lance A.

AU - Chang, Ted T.

AU - Embry, Scott

AU - Hudson, Kathleen

AU - Bradley, Yong

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Although positron emission tomography (PET) imaging may not be used in the diagnosis of breast cancer, the use of PET/computed tomography is imperative in all aspects of breast cancer staging, treatment, and follow-up. PET will continue to be relevant in personalized medicine because accurate tumor status will be even more critical during and after the transition from a generic metabolic agent to receptor imaging. Positron emission mammography is an imaging proposition that may have benefits in lower doses, but its use is limited without new radiopharmaceuticals.

AB - Although positron emission tomography (PET) imaging may not be used in the diagnosis of breast cancer, the use of PET/computed tomography is imperative in all aspects of breast cancer staging, treatment, and follow-up. PET will continue to be relevant in personalized medicine because accurate tumor status will be even more critical during and after the transition from a generic metabolic agent to receptor imaging. Positron emission mammography is an imaging proposition that may have benefits in lower doses, but its use is limited without new radiopharmaceuticals.

UR - http://www.scopus.com/inward/record.url?scp=84883372475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883372475&partnerID=8YFLogxK

U2 - 10.1016/j.rcl.2013.06.003

DO - 10.1016/j.rcl.2013.06.003

M3 - Review article

VL - 51

SP - 781

EP - 798

JO - Radiologic Clinics of North America

JF - Radiologic Clinics of North America

SN - 0033-8389

IS - 5

ER -